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Expert Opinion: Recommendation of diabetes 
experts on the use of FreeStyle Libre  
in diabetic patients in Poland
Introduction 
The primary goal of diabetes treatment is to pre-
vent the development of chronic complications of dia-
betes, which can be attained by, among other things, 
maintaining blood glucose values within the target 
range. Glycated hemoglobin (HbA1c) is a commonly 
used risk marker for diabetes complications; however, 
this parameter has major limitations.
Hemoglobin A1c value, reflecting blood glucose 
levels during the 3 months preceding the measurement, 
averages all episodes of hyperglycemia and hypogly-
cemia. This parameter does not reflect the variability 
of glycemia and does not provide precise information 
about the time spent in the target range of blood 
glucose. Patients with diabetes, especially those with 
type 1 diabetes, may experience considerable glycemic 
variability, with blood glucose levels changing rapidly 
from hyper- to hypoglycemia and vice versa.
Hypoglycemia not only causes acute neurovegeta-
tive and neuroglycopenic symptoms, but also is associ-
ated with the risk of falls, injuries, loss of consciousness 
or even death. In addition, it can lead to long-term 
consequences, which include cardiovascular events, 
and sometimes to episodes of depression. Rapid fluc-
tuations in blood glucose are also associated with dis-
placement of water in the body — dilution or increased 
concentration of fluids of various compartments and 
rapid changes in concentrations of substances other 
than glucose, which also carries a risk for the patient.
Current glucose monitoring has been integral part 
of adequate diabetes treatment for decades. Proper 
self-monitoring of blood glucose (SMBG) requires 
regular patient education in this regard, with par-
ticular emphasis on the frequency of blood glucose 
measurements and the interpretation of the results. 
Measured blood glucose values provide the basis for 
day-to-day modification of nutrition, physical exercise 
and insulin dose. Patients treated with multiple daily 
insulin injections or continuous subcutaneous insulin 
infusion (CSII) should perform a daily blood glucose 
profile, which means for many of them performing 
10 or more measurements a day. These procedures 
are time-consuming, invasive, painful and causing 
discomfort in everyday life.
The FreeStyle Libre system is an excellent solution 
to these problems. It offers continuous glucose moni-
toring using a sensor-based technology to measure 
glucose level in interstitial fluid. When the patient scans 
the sensor to obtain glucose values, he or she simulta-
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neously receives a retrospective analysis of the glucose 
levels in the form of a continuous record. Information 
about the trends of glycemic variability presented by 
the device provides additional benefits related to im-
proved effectiveness and safety of the therapy. Thanks 
to the possibility of generating an Ambulatory Glucose 
Profile (AGP), this system allows to precisely assess the 
level of metabolic control over the 90 days preceding 
the measurement, which corresponds to the period 
covered by HbA1c value. The accuracy of the system 
allows for the current calculation of the HbA1c value 
corresponding to the laboratory measurement of this 
parameter. This means that the useful, although imper-
fect, parameter which is HbA1c can be monitored on an 
ongoing basis and integrated with the patient’s SMBG.
Flash Glucose Monitoring 
FreeStyle Libre is a Flash Glucose Monitoring (FGM) 
system. It is designed to measure glucose level in the 
interstitial fluid in patients with diabetes aged ≥ 4 
years, also in pregnant women. It can also be used in 
other patients, without diabetes, who are at risk of 
glycemic disorders, e.g. in patients with prediabetes 
or recurrent hypoglycemia caused by hormonal or 
metabolic disorders.
The system consists of a reader, a device for wireless 
retrieval of data regarding glucose levels, and a sensor 
measuring the level of glucose in interstitial fluid of the 
subcutaneous tissue, which is worn on the skin.
The system converts the result of the measurement 
to the corresponding blood glucose value. It does not 
require user verification with blood glucose values.
Therapeutic benefits for patients
 — The sensor continuously measures the glucose 
level for 14 days;
 — Glucose monitoring without finger pricks trans-
lates in clinical practice into considerably more 
frequent measurements of glucose levels and 
more than 90% reduction in the number of blood 
glucose test strips (the IMPACT trial);
 — The system does not require finger prick cali- 
bration;
 — Computer software enables generating reports 
(glucose history), including AGP reports;
 — Trend arrows indicates whether glucose level is 
increasing or decreasing and show trend dynam-
ics, which significantly facilitates assessment of 
the risk of hypoglycemia in the next few hours 
(thanks to these data patients also learn how 
their body reacts, for example, to a specific diet or 
exercise; therefore, the system plays educational 
role as well);
 — It is also possible to measure the level of glucose 
and ketones with the reader directly from the 
blood using test strips that are available and re-
imbursed in Poland;
 — Readings can be obtained in a discreet way, 
through clothing. It is a comfortable solution, 
meeting the expectations of patients and their 
families — it allows for avoiding the violation of 
privacy and stigmatization of patients;
 — Use of the system is easier and more conveni-
ent compared with test strips; therefore, it pro-
motes more frequent measurements (more than 
3-fold increase in the number of measurements 
performed) and improved glycemic control. Ad-
ditionally, awakening the patients (e.g. a child) by 
a caregiver at night can be avoided;
 — Full service for patients using FreeStyle Libre sys-
tem (warranty/replacement, toll-free helpline).
Benefits demonstrated in clinical trials 
Data from clinical trials indicate that the FreeStyle 
Libre system improves the effectiveness and safety of 
therapy in patients with type 1 and type 2 diabetes. 
It has been observed that the use of FreeStyle Libre 
decreased not only the number of hypo- and hypergly-
cemic episodes, but also reduced time spent in hypo- 
and hyperglycemia, including nocturnal episodes. It 
should be emphasized that hypoglycemia not only is 
a life-threatening condition (severe hypoglycemia) and 
decreases the patient’s quality of life, but also is an 
important risk factor for the development of chronic, 
especially macroangiopathic, complications of diabetes. 
At the same time, the use of the FreeStyle Libre system 
resulted in extend time in the target glucose range, 
i.e. 70–180 mg/dL. Favorable changes were observed 
almost immediately after the readings from the device 
were opened to its users. Importantly, these changes 
were sustained and persisted for 6 months of follow-
up (the IMPACT trial). The reduction of the time and 
number of hypoglycemic episodes has been achieved 
without insulin dose reduction or increase in HbA1c. 
Extended time in normoglycemia with the reduction 
of the risk of hypo- and hyperglycemic episodes was 
also associated with a decrease in glycemic variability, 
a parameter now considered as an integral element in 
the evaluation of metabolic control of diabetes and an 
important prognostic factor for the development of 
diabetic complications. It is worth noting that glycemic 
variability is calculated automatically, similarly to the 
estimated HbA1c (eHbA1c), a parameter which in turn 
shows a far-reaching correlation with the biochemically 
determined HbA1c value and can be obtained imme-
diately after scanning FreeStyle Libre sensor without 
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having to waiting for a biochemical test result. The 
use of the FreeStyle Libre also allowed for a significant 
reduction in the number of test strips used, compared 
with using only the traditional method (a glucose me-
ter). Several studies indicate that the FreeStyle Libre 
system provides glycemic monitoring that is accurate 
and consistent with the reference measurements for 14 
days without the need to calibrate the device.
Surveys conducted among users have shown that 
patients appreciate the ease and convenience of meas-
urements with the FreeStyle Libre system. It has been 
also observed that these patients more often follow 
the guidelines for glycemic monitoring than in the 
case of measurements performed using the conven-
tional method. In the IMPACT trial, patients with type 1 
diabetes using the FreeStyle Libre system measured 
glucose levels on average 15.1/day, which is much more 
often than in patients in the glucose meter group (5.6 
measurements/day). The results of this survey and ques-
tionnaires assessing the quality of life also highlight the 
importance of the painlessness of measurements and a 
greater amount of information on glycemic variability, 
which allows patients to optimize their blood glucose 
levels. Ease of measurement and access to information 
also translated into clear preferences of patients, over 
90% of whom declared that they prefer FreeStyle Libre 
rather than the traditional SMBG based on a glucose 
meter. Participants of the study also pointed to the 
increased awareness of the risk of hypoglycemia, se-
curity and privacy offered by the FGM device and the 
fact that it did not hinder usual daily-life activities, and 
even facilitated them by improving diabetes safety. The 
opinions of FreeStyle Libre users were similar regardless 
of the age of the respondents.
Patient register (Real World Data)  
— a confirmation of clinical data
Data from real-world medical practice confirm the 
above conclusions from clinical trials: the FreeStyle Libre 
system allows improving glycemic control. Particular 
attention is paid to the results of Dunn 2017 analysis, 
covering almost 51 thousand readers (about 280,000 
sensors), indicating the relationship between the 
frequency of scans and the improvement in glycemic 
parameters. These results are all the more important 
because the frequency of scans in this analysis was even 
higher (an average of 16.3/day) than in the IMPACT 
study (an average of 15.1/day).
Interpretation of trends
Patients for whom the basis for glucose control is 
SMBG using a glucose meter make their therapeutic de-
cisions based on the real-time but single blood glucose 
value. Lack of information about the rate and direction 
of glycemic changes makes it difficult for patients to 
determine correctly the dose of insulin.
The FreeStyle Libre system provides two very impor-
tant pieces of information beyond the current glucose 
level. The reader screen displays a graph showing the 
results of glycemia from the last 8 hours and trend ar-
rows indicating the direction and rate of changes in the 
glycemic level. The patient should immediately modify 
his or her therapy taking into account this information.
In patients treated with functional intensive insulin 
therapy, modifications of therapy based on glycemic 
trends should include: 
 — change of meal-time and correction doses of in-
sulin; 
 — intake of fast-acting carbohydrates or skipping 
a meal; 
 — considering physical activity. 
Patients treated with personal insulin pumps may 
additionally modify the basal rate of insulin infusion 
and consider earlier replacement of infusion set.
Proper interpretation of trends by patients results 
in the reduction in the incidence of hypo- and hyper-
glycemia, decreased glycemic variability and improved 
time in target range. The use of glycemic trends should 
translate into a reduction in the incidence of acute 
diabetic complications and a reduction in the risk 
of development and progression of chronic diabetic 
complications. This information is also very useful for 
patients driving vehicles. 
Considering all the above factors, patients should 
be educated on how to interpret glycemic trends. Cur-
rently, guidelines are being developed regarding pro-
posed modifications of therapeutic decisions depend-
ing on the rate and direction of glycemic changes. The 
current interpretation of glycemic trends by patients 
will add a new dimension to diabetes self-control.
Ambulatory Glucose Profile:  
benefits for doctors 
FreeStyle Libre enables performing systemic evalua-
tion of the therapeutic process and treatment outcomes 
regarding blood glucose control in diabetic patients. 
FreeStyle Libre is the only system available on the Pol-
ish market which presents data using internationally 
recognized standardized approach to the analysis of 
glucose data — Ambulatory Glucose Profile (AGP) — 
both directly in the device and in the available computer 
software.
AGP provides a visualization of changes in glucose 
levels in the patient’s averaged day of life. It is created 
on the basis of a daily chart summing up the results 
of glycemic measurements from many days or weeks 
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in one 24-hour chart. AGP shows averaged daily gly-
cemic variability for the 10th, 25th, 50th, 75th and 90th 
percentiles (the graph is generated with 5 percentile 
lines). Generated in this way and superimposed glucose 
curves show how often the glucose values are outside 
the target range (low or high values) and how often 
they fall within the target range. The visualization of the 
AGP reveals the tendencies to hypo- and hyperglycemia 
that could not be detected based on HbA1c value. Scien-
tific reports emphasize the need to prevent significant 
fluctuations of blood glucose, because it is considered 
as the most important factors contributing to the early 
onset of serious complications of diabetes. These goals 
cannot be achieved by assessing the level of glycemic 
control using only HbA1c monitoring, and AGP provides 
a very valuable supplement. Ambulatory glucose profile 
facilitates detecting hypo- and hyperglycemic trends, 
which allows the identification of glycemic patterns 
and proper patient education. Reports from clinical 
trials indicate that AGP has introduced an effective 
standard for analyzing glucose data and provides clini-
cally relevant information about the patient’s condition. 
The FreeStyle Libre® system due to its functionality (the 
device stores the reading every 15 minutes; it stores 
90 days of glucose data) enables widespread use and 
practical application of the AGP protocols.
Summary of this section:
 — a glucose graph and trend arrows showing blood 
glucose changes in the last few hours provide the 
basis for making therapeutic decisions;
 — the system offers the analysis of standardized 
AGP, which enables: 
• identification of glycemic patterns and ad-
equate patient education (it helps patients to 
understand how daily activities impact blood 
glucose levels);
• more detailed evaluation of the therapeutic 
process by the healthcare professionals.
New standard of glucose monitoring  
supplemented by SMBG
The FreeStyle Libre system, if it is permanently used 
by the patient, can replace the conventional glucose 
meter-based SMBG. This applies to patients with type 1 
and type 2 diabetes treated with intensive insulin 
therapy except for the situations listed below.
In the following situations current readings from 
FreeStyle Libre should be verified with the finger prick 
test using a blood glucose meter: 
 — if hypoglycemia or impending hypoglycemia is re-
ported by FreeStyle Libre;
 — if the symptoms do not match the FreeStyle Libre 
system readings; symptoms that may be caused 
by low or high blood glucose must never be ig-
nored.
 — during times of rapidly changing glucose levels 
when interstitial fluid glucose levels may not ac-
curately reflect blood glucose levels; when blood 
glucose decreases rapidly, sensor reading may be 
higher than blood glucose level; and conversely, 
when blood glucose increases rapidly, sensor 
readings may be lower than blood glucose level.
Indication for use (patient groups) 
FGM is indicated for use in the following groups 
of patients:
 — patients with diabetes treated with intensive 
functional insulin therapy (multiple daily insulin 
injections, insulin pump therapy), regardless the 
type of diabetes;
 — pregnant women with diabetes;
 — patients with diabetes treated with conventional 
insulin therapy (2–3 injections daily), who are able 
to adjust insulin doses.
Other special groups of patients with an indication 
for the use of FGM:
 — diabetic patients with the fear of needles or fear 
of hypoglycemia;
 — patients with diabetes who drive the vehicles, 
leading an active lifestyle, working in shifts;
 — patients with diabetes who require constant 
care (children, people with physical or mental 
disabilities);
 — patients with diabetes and visual impairment or 
blindness (text-to-speech option)
 — elderly patients with diabetes (FGM systems are 
easy to operate), also in senior care facilities and 
nursing homes.
Potential limitations of the system  
and their importance
FreeStyle Libre is similar in many respects to other 
interstitial-glucose-monitoring systems, but it also has 
some unique features. The FreeStyle Libre sensor is a 
transmitter that connects wirelessly to the reader; it 
does not have to be recharged and can be worn on 
the skin for 14 days.
Exceptionally high accuracy of measurements and 
trend indications without calibration as well as 14- 
-day life span of a sensor are advantages obtained at 
the expense of limiting energy expenditure, resulting 
mainly from the lack of continuous transmission of 
data and audible alarms. On the other hand, this solu-
tion is simple from a technical point of view and can 
be easily integrated in the system as it is successively 
improved. Another feature simplifying the use of the 
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FreeStyle Libre system is FreeStyle LibreLink application 
which enables the caregivers to trace the patient’s 
blood glucose readings and support the patient in 
daily diabetes control. This is particularly important for 
remote parental control over children with diabetes or 
for caregivers of elderly patients. 
Noteworthy is the fact that glucose measurements 
are automatically registered every 15 minutes, which is 
less frequently than in continuous glucose monitoring 
(CGM) systems, but the time interval is similar to that of 
natural changes of glucose concentration in interstitial 
fluid (where the measurement is actually performed) 
in response to blood glucose fluctuations. This can 
also result in higher accuracy of the measurement and 
more reliable prognosis of glycemic changes (trend), 
because the device analyzes a 15-minute periods rather 
than, for example, 5-minute periods. In addition, this 
automatic registration does not exclude much more 
frequent measurements made by the patient by scan-
ning the sensor, even every 1 minute, which is not 
possible when using CGM systems. Frequent (every few 
minutes) monitoring of glucose levels may be useful in 
special situations.
There is only one site for administration of the 
FreeStyle Libre sensor recommended by Abbott — on 
the back of the arm. This is important for optimal ac-
curacy of measurements, because this location was 
associated with the best results in manufacturer’s 
quality tests. On the one hand, this can be considered 
as a limitation, although the use of sensors inserted 
subcutaneously do not cause significant tissue injury 
and therefore the limitation of rotation areas, even for 
smaller children, is not a problem. On the other hand, 
placing sensor within previously examined areas of the 
body, with known characteristics of vascularization and 
involvement in the glycemic balance, results in greater 
accuracy and repeatability of measurement results. If 
the user, in spite of Abbott’s suggestions, places the 
sensor in another area for important reasons, the sensor 
will still work, although more frequent verifications of 
obtained readings with the result of the glucose meter 
measurements are required, especially in the case of 
abnormal blood glucose values.
FreeStyle Libre also stands out from other CGM 
systems due to its flat sensors with rounded edges, 
well-fitting to the body. Thanks to all these features the 
sensor is better secured on the skin and less susceptible 
to accidental detachment when, for example, caught 
by clothes, etc.
The biggest limitation preventing the widespread 
use of the system is the lack of reimbursement for pa-
tients, which limits its availability. The reimbursement 
would be, at least partially, offset by reducing the 
cost of test strips for glucose meters. The example of 
patients already using FreeStyle Libre shows that the 
use of strips for glucometers decreases about 10 times. 
They are not needed for FreeStyle Libre calibration, and 
are used, along with reader’s indications, only in the 
specific situations listed above. Moreover, the Libre 
reader not only can be used as a glucometer using 
glucose strips (Optium Xido), but also can measure 
ketones (b-hydroxybutyric acid) in the blood (Optium 
Xido b-ketone strips), which allows determination of 
significant hazards for the patient. In addition, there is 
still a need to improve diabetes control and reduce the 
costs resulting from the development of complications 
and acute, transient, often life-threatening conditions 
(costs of outpatient visits and hospitalizations). Cur-
rently in Poland, the reimbursement of CGM systems 
is limited to type 1 diabetes patients in a specific age 
range who are users of personal insulin pumps. It also 
requires meeting additional criteria related to diabetes 
control. These conditions discriminate against patients 
with type 1 diabetes who have poor metabolic control 
or do not have (for various reasons) a personal insulin 
pump. They also discriminate against patients with 
type 2 diabetes treated with insulin, usually injected 
with pens. It should be remembered that many pa-
tients with type 2 diabetes are also treated intensively 
with insulin and they also require continuous monitor-
ing of therapy.
Software
Since the second half of 2018, patients using 
FreeStyle Libre in Poland can use innovative digital 
solutions: FreeStyle LibreLink and LibreLinkUp applica-
tions available on Android and iOS systems as well as 
the LibreView system allowing for comprehensive data 
analysis and on-line access to glucose data.
Below are the features of these applications and 
the system:
The FreeStyle LibreLink application allows users 
of the FreeStyle Libre system to scan the sensor using 
a smartphone, providing greater convenience and dis-
cretion. It also allows the patient to reduce the cost of 
blood glucose monitoring, because there is no need to 
use a separate reader to monitor glucose.
The benefits for patients resulting from using this 
application:
 — patients can use FreeStyle LibreLink on their 
smartphone instead of or simultaneously with the 
FreeStyle Libre reader; 
 — rich patient interface is available from a large 
high-resolution touch screen;
 — patients can easily add notes to track meals, insu-
lin doses, exercise and other events;
Grzegorz Dzida et al., Expert Opinion: Recommendation of diabetes experts on the use of FreeStyle Libre in diabetic patients in Poland
137
 — cooperation of FreeStyle LibreLink with LibreLink-
Up enables connection with caregivers;
 — text-to-speech option converts glucose readers 
into spoken audio, which is important for users 
who are blind or have impaired vision.
Some examples of reports available to the patient 
using the FreeStyle LibreLink application are presented 
in Figure 1. 
LibreLinkUp is a mobile application that allows 
parents and caregivers to remotely monitor glucose 
readings in patients who scan the sensor using the 
FreeStyle LibreLink application.
Figure 2 shows an example screenshot from 
a smartphone used by a caregiver working with the 
FreeStyle LibreLinkUp application.
LibreView is a cloud-based diabetes control system 
offered by Abbott and Newyu, Inc. LibreView provides 
a secure data repository for the FreeStyle LibreLink ap-
plication and enables easy sharing of glycemic data with 
health care professionals or other people. The data is 
automatically sent to the LibreView system when the 
phone is connected to the Internet.
The main benefits of using this system are:
 — glucose data can be simply uploaded from the 
reader via a computer and accessed from any-
where from any internet-connected device; 
 — the glucose data of patients using FreeStyle Libre-
Link application will be automatically transferred 
to their LibreView account each time the FreeStyle 
Libre sensor is scanned;
 — clear, easy-to-read reports which allow the patient to 
discover glucose patterns and trends immediately;
 — optimization of treatment plans thanks to re-
mote patients monitoring and cooperation with 
a healthcare team. 
Using the above-described applications and the 
system allows for remote control of glycemia with 
tools perfectly matching the concept of telemedicine, 
which not only significantly increases patient safety, 
but also reduces direct and indirect expenses by the 
public payer. Additionally, this technology provides 
real-world data showing actual effects of the use of 
a specific medical technology.
Education
Type 1 diabetes results from destruction of pancre-
atic beta cells. These cells are the source of insulin and 
a perfect natural regulator of its presence and access 
Figure 1. Some examples of reports available to the patient using the FreeStyle LibreLink application
Low glucose eventsCurrent glucose reading AGP analysis Time in target
Figure 2. Example screen available to a caregiver using the 
LibreLinkUp application
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to all cells in various organs. The beta cells precisely 
regulate insulin secretion according to the changing 
needs of the body. During the initial stage of type 2 
diabetes, beta cells produce insulin in excessive amount. 
The progression of the disease is characterized by a dis-
turbed profile of and a progressive decrease in insulin 
secretion. Thus, in the treatment of both type 1 and 
type 2 diabetes, it is necessary not only to supplement 
insulin, but also replace the lost regulatory function 
of the beta cells.
The way to improve this situation is proper edu-
cation of the patients and/or their caregivers so that 
they understand the role of insulin and can predict the 
effects of its administration, in particular in relation 
to meals and physical exercise. It is also important to 
anticipate a change in insulin requirements during 
additional illness or in special situations. A particular 
difficulty in good diabetes therapy is associated with 
individual differences in the course of the disease and 
various life situations.
In practice this means that diabetes education, 
which is an integral part of the treatment of a patient 
with diabetes, must also be individualized. The pa-
tients actively participate in treatment, because they 
ultimately make therapeutic decisions. Their task is 
to observe their bodily reactions to meals, physical 
activity and, finally, insulin dosing, and sometimes also 
effects of other drugs influencing glycemia. These ob-
servations as well as drawing conclusions from them 
and constant modification of the therapy are based 
largely on glucose monitoring. The patient has to 
verify the recommendations received from the thera-
peutic team in real life, which is done by assessing 
the glycemic effects of the therapy. In healthy people, 
pancreatic beta-cells control glycemia and constantly 
regulate insulin secretion. In diabetes, FreeStyle Libre 
allows the user to imitate the natural mechanism of 
glycemic control. Indeed, it supports the patient’s 
therapeutic decisions. FreeStyle Libre, by displaying 
real-time glycemic values, indicating the anticipated 
glycemic trends, storing these data in memory and 
offering the possibility of reviewing data from the past 
few hours, 24 hours or many days allows the patient 
to successively adjust his or her self-management and 
constantly improve glycemic control. This applies to 
evaluation of the risk of hypo- and hyperglycemia 
episodes, their amplitude and timing, identification 
of repeating patterns of normal and abnormal blood 
glucose values.
Patient self-education activity aiming at expand-
ing their knowledge about diabetes is also needed. It 
involves arranging situations that are associated with 
changes in insulin dosing, diet or physical activity in 
order to carefully observe glycemic effects and evaluate 
the sensitivity to insulin, calculate insulin/carbohydrate 
ratio, assess the hypoglycemic effect of exercise etc. 
Thanks to the FreeStyle Libre system, diabetic patients 
can easily track glycemic changes even in very narrow 
time intervals, store them in the system’s memory, 
and then draw conclusions about modifications or 
continuation of therapy i.e. insulin dosing, diet and 
physical activity.
The FreeStyle Libre system also allows the calcula-
tion of the corresponding HbA1c value based on numer-
ous glucose readings recorded by the sensor; its high 
accuracy has been confirmed by laboratory tests. The 
educational value of this efficient HbA1c calculation is 
to indicate whether the therapeutic goal expressed by 
this parameter is achieved. It allows the patient to un-
derstand the relationship between the calculated HbA1c 
value and his or her glucose profile — its amplitude, 
episodes of hypo- and hyperglycemia, etc. This makes 
the interpretation of HbA1c parameter more valuable 
and informed.
Summary
On the basis of clinical trials, scientific evidence and 
experience from everyday practice, the use of FreeStyle 
Libre is recommended as a glucose monitoring system 
in patients with type 1 and type 2 diabetes treated 
with intensive insulin therapy. FreeStyle Libre supports 
treatment and can contribute to:
 — improvement in diabetes control by decreasing 
mean blood glucose levels and HbA1c;
 — reduction of the number of hypoglycemic epi-
sodes and time spent in hypoglycemia; it is 
particularly relevant to patients with frequent 
hypoglycemic episodes and hypoglycemia una-
wareness;
 — reduced glycemic variability;
 — potential decrease in long-term complications of 
diabetes;
 — improved patient quality of life and safety.
We express the opinion that the FreeStyle Libre sys-
tem should be widely available, also taking into account 
its affordability, for Polish patients with type 1 and 
type 2 diabetes treated with intensive insulin therapy.
The Expert Group was established by Abbott Labo-
ratories Polska to express the above opinion as part of 
the meeting of the Advisory Committee, which was 
held in Warsaw on November 21, 2017 and on March 
23, 2018.
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